Diabetic Microangiopathy - Etiopathogenesis, New Possibilities in Diagnostics and Management by Jarmila Vojtková et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
4 
Diabetic Microangiopathy – Etiopathogenesis, 
New Possibilities in Diagnostics and 
Management 
Jarmila Vojtková, Miriam Čiljaková and Peter Bánovčin 
Jessenius Faculty of Medicine in Martin, Department of Children and Adolescents 
Slovakia 
1. Introduction 
Diabetic microangiopathy is characterized as a disorder of small vessels. It is one of the 
major chronic diabetic complications involving diabetic neuropathy, retinopathy and 
nephropathy (Adeghate et al., 2006). Its prevalence has rising tendency even in children 
population and is possitivelly associated with duration of diabetes mellitus.  
Diabetic neuropathy affects peripheral nerves (sensory, motor, autonomic) so all organ 
systems can be affected. In childhood, subclinical forms are typical when no clinical 
symptoms are evident, however sensitive diagnostic methods can detect them. Later, 
autonomic and sensory-motor neuropathy is very common (see the classification in table 1). 
Some forms of diabetic neuropathy are presented in 40 – 90% of patients with diabetes 
duration ten years and more and even in 5% of patients after one year of diabetes 
diagnostics.  
 
Subclinical neuropathy 
Clinical neuropathy 
Symetric 
Distal symetric neuropathy 
sensoric 
motoric 
mixed 
Autonomic neuropathy 
Proximal symetric neuropathy 
Acute painful neuropathy 
Asymetric 
Cranial neuropathy 
Peripheral mononeuropathy 
Radiculopathy 
Asymetric proximal motoric neuropathy 
Mixed 
Table 1. Classification of diabetic neuropathy (Rybka, 2007) 
Diabetic retinopathy is the most frequent cause of new cases of blindness among adults 
aged 20 – 74. It progresses from mild nonproliferative abnormalities characterized by 
increased vascular permeability to moderate and severe nonproliferative retinopathy 
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characterized by vascular closure to proliferative retinopathy with typical new blood vessels 
growth (table 2). The prevalence of retinopathy is noticed in 2 – 7% of diabetic patients after 
two years, in 50% of patients after ten years and in 75% of patients after twenty and more 
years of diabetes duration.  
Diabetic nephropathy is characterized by glomerular, tubular and mesangial damage 
accompanied by basement membrane thickening, mesangial expansion and hyalinisation of 
glomerular intercapillary connective tissue. In clinical practice, progressive kidney disease 
with proteinuria, hypertension and gradual decrease in renal functions is typical (table 3). 
Manifest nephropathy is presented in 30 – 35% of patients with diabetes duration over 
fifteen years.   
 
 Eye background 
Non-proliferative 
DR 
Mild 
 
Moderate 
 
Severe 
 
Microaneurysmas, microhemorrhages, intraretinal hemorrhage, 
venous abnormalities  
 
Vessel changes at macula area, hard exudates, „cotton“ exudates 
 
Intraretinal microvascular abnormalities (IRMA), retinal ischemia 
Proliferative DR 
Beginning 
 
High risk 
 
Retinal or papilar neovascularisation  
 
Traction amotio of retina, intravital hemorrhage 
Diabetic 
maculopathy 
Macular edema 
Table 2. Clinical stages of diabetic retinopathy (DR) (Rybka, 2007) 
 
 characteristics Urinary findings 
1. Latent stage  
(hyperfiltration-
hypertrophic) 
increase GF about 10 – 40%, 
ultrasound hypertrophic of 
kidneys, slightly enlargement of 
basal membrane  
transitory microalbuminuria  
30 – 100 mg/day, resp.  
20 – 70  µg/min 
2. Incipient diabetic 
nephropathy 
decrease GF, common 
hypertension (mainly diastolic), 
progression in  enlargement of 
basal membrane 
permanent 
microalbuminuria  
30 – 300 mg/day, resp.  
20 – 200 µg/min 
3. Manifest diabetic 
nephropathy 
Next decrease GF, hypertension 
progression, sclerotisation of 
many glomerules  
proteinuria >0,5 g/day 
4. Chronic renal 
insufficiency even 
kidney failure  
Terminal phase, uremia, dialysis  
necessary 
proteinuria >0,5 g/day, 
serum creatinine > 200 
µmol/l 
Table 3. Clinical stages of diabetic nephropathy (Rybka, 2007) 
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2. Etiopathogenesis 
The etiopathogenesis of diabetic microangiopathy is complex (Figure 1) and since now not 
completely understood. Long lasting hyperglycemia triggers the variety of pathways – non-
enzymatic glycation of proteins, oxidative stress, polyole pathway and sorbitol production, 
activation of proteinkinase C production, decrease of vasodilatation products (nitric oxide, 
prostaglandines), decrease of myoinositol origin, change in Na+K+ATP-ase activity causing 
the endothelial damage and so the microangiopathy with disorder in many organ systems 
(Brownlee, 2005). However, according to the clinical experience, some patients with short 
duration and adequate compensation of diabetes mellitus (DM) have symptoms of 
microangiopathic complications, and some despite long duration and insufficient 
compensation do not suffer from any complications. That is why other factors have been 
considered as important in pathogenesis – genetic, epigenetic or immunologic factors 
(Villeneuve & Natarajan, 2010). According to Diabetes Control and Complication Trial 
(DCCT Research Group, 1993), important risk factors for microvascular complications are 
cigarette smoking and genetic susceptibility to hypertension at early stages of diabetes and 
poorer glycemic control, higher blood pressure and unfourable lipid profile at later stages.   
 
Fig. 1. Etiopathogenesis of diabetic microvascular complications 
2.1 Advanced glycation end products 
Advanced glycation end products (AGEP´s) are heterogeneous group of modified proteins, 
lipids and nucleic acids arisen within intracellular hyperglycemia by non-enzymatic 
Maillard reaction. The initial product of this reaction is called a Schiff base, which 
spontaneously rearranges itself into an Amadori product. These initial reactions are 
reversible depending on the concentration of glucose and reactants. Series of subsequent 
reactions (dehydratation, oxidation, reduction, other arrangements) lead to the formation of 
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AGEP´s. As precursors AGEP´s have typical ability for covalent crosslink formation 
between proteins, modified products have altered their structure and biological function 
(Peppa et al., 2003). Except endogenously formed AGEP´s, another source is exogenous like 
tobacco smoke and certain food. Nearly 10% of AGEP´s is absorbed through intestinal 
mucose from food like meat with high content of fat, meals prepared at high temperature 
(grilled, fried) (Klenoviscová et al., 2008). Contrary, fruit, vegetable and boiled, braised or 
steamed meals have noticably lower content of AGEP´s.  
AGEP´s increase vascular permeability and production of growth factors and cytokines. 
They can modify extracellular matrix by changing its structure, solubility and charge 
leading to cummulation of collagen, fibronectin or laminin. Abnormalities in glomerular 
extracellular matrix lead to higher proliferation of mesangial cells and to increase in 
glomerular permeability which correlates with microalbuminuria (Cvetkovic et al., 2009). 
Glycated collagen can change the filtration abilities of glomerular basement membrane and 
can increase the binding of circulating plasmatic proteins. 
Receptors for AGEP´s (RAGE) were found on vascular endothelial cells, macrophages, 
mesangial cells or smooth muscle cells. Interaction between AGEP´s and RAGE causes 
increase of oxidative stress, activation of transcriptional factor NFκB and expression of 
inflammatory genes for cytokines or growth factor inducing NO synthetase. Binding 
AGEP´s on neural receptors RAGE causes the induction of oxidative stress, protein kinase C 
and NFκB responsible for inflammatory processes and apoptosis of nerve cells. As vasa 
nervorum supply nerve cells, diabetic neuropathy is caused also by changes of endothelial 
cells.         
2.2 Polyole pathway 
Polyole pathway has physiologically role in reduction of toxic aldehydes arisen due to 
reactive oxygen species (ROS) into inactive alcohols. An initial and rate limiting enzyme of 
this pathway is aldose reductase which uses reduced form of nicotinamide adenine 
dinucleotide phosphate (NADPH) as a cofactor. Raising intracelular concentration of 
glucose increases the activity of this enzyme by which glucose is reduced into sorbitol and 
next into fructose. Elevated activity of aldose reductase leads to decrease of concentration of 
NADPH (needed also for glutathione reductase activity), by which intracelular oxidative 
stress is raising. Accumulation of osmotic active sorbitol and fructose causes the reduction 
of myoinositol and taurine in nerve fibers and decrement in membrane Na+K+ATP-ase 
activity. These processes lead to slow of axonal transport. Also oxidative stress and protein 
kinase C induce the sorbitol origin, apoptosis of nerve cells and microvascular dysfunction.  
2.3 Oxidative stress 
Biochemical and metabolic changes in diabetes duration cause the increase of reactive 
oxygen species (ROS) origin and also decrease of antioxidant systems activity. ROS, 
especially superoxid anion cause damage of endothelial cells leading to diabetic 
microangiopathy. In hyperglycemia condition endothelial cells are exposed to major glucose 
turnover, from glycolysis through pyruvate decarboxylasis into Krebs cycle with 
consequence of higher transport of electrones through mitochondrial enzymes. Electron-
overloaded mitochondria produces significant amount of superoxid anions that lead into 
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nitric oxid decrese, DNA damage, AGEP´s formation, protein kinase C activation and even 
polyole pathway activation.  
Oxidative stress induces mRNA expression of tissue growth factor ǐ1 (TGF- ǐ1) and 
fibronectin playing important role in renal damage as they increase the extracellular matrix 
production. Overproduction of ROS alters the mesangial cells – the most important in 
diabetic nephropathy development – and supports the cell processes leading to apoptosis 
(Ha et al., 2008). ROS increase protein kinase C (PKC) activity in mesangial and glomerular 
cells and PKC stimulates the hyperproduction of ROS. These changes together with non-
enzymatic glycation of proteins lead to kidney hyperperfusion, hyperfiltration, extracellular 
matrix cummulation, renal vessels vasoconstriction, reconstruction of renal structure and 
even nephrosclerosis.  
Oxidative stress can directly damage neurocyte myelin, macromolecules and membranes of 
nerve cells and induces their apoptosis. Considering the blood supply of nerves through 
vasa nervorum, also dysfunction of endothelial cells contributes to diabetic neuropathy.  
Microvasculature of retina consists of two types of cells – endothelial and pericytes. Early 
signs of diabetic retinopathy are characterized by dysfunction of pericytes and consequently 
by dysfunction of endothelial cells. Oxidative stress together with AGEP´s induce nuclear 
factor NFκB and apoptosis of pericytes and endothelial cells. They contribute to thickening 
of retinal basement membrane, formation of acellular capillaries or microaneurysmas. 
Pigment epithelium derived factor (PEDF), glycoprotein of protease inhibitors family, is 
extracellular part of retina and was found in vitreous and intraocular fluid. PEDF can inhibit 
the growth and migration of endothelial cells, has antiangiogenic activity, cytoprotective 
and also antioxidant effect. Oxidative stress causes the decrese in PEDF leading to 
dysfunction and apoptosis of pericytes. The stability of vascular integrity is provided by 
angiopoietin 1 (ang-1), while angiopoietin 2 (ang-2) is its natural antagonist which break the 
connection between pericytes and endothelium (Patel et al., 2005). Oxidative stress and ROS 
increase the ratio of ang-2 / ang-1 in pericytes whereby impair the stability of retinal cellular 
structure.  
2.4 Protein kinase C 
Protein kinase C (PKC) belongs to the family of kinases responsible for intracellular 
signalisation in the cardiovascular, immunologic or other systems. Till now, twelve isoforms 
of PKC have been characterized according to the structure and cofactor requirements. The 
activator of the most of PKC isoforms is diacylglycerol. De novo formation of diaclyglycerol 
is enhanced in higher concentration of intracellular glucose with the consequence of increase 
activity of isoforms PKC-ǐ1 and PKC-ǒ. PKC can be activated also by some growth factors, 
superoxid (induced by hyperglycemia) and by AGEP´s. PKC mediated phosphorylation of 
substrate proteins triggers a cascade of pathophysiological responses. Isoforms PKC-ǐ1 and 
2 deteriorate the blood flow through retina and kidneys, increase the capillary leak, induce 
the production of extracellular matrix and activate many inflammatory cytokines what 
contribute to microvascular damage.  
Formation of vascular endothelial growth factor (VEGF), a cytokine with major role in 
retinal leakage, angiogenic activity and neovascularisation,  is at least partly PKC 
dependent. PKC activates the release of adhesion molecules, tissue growth factor ǐ, 
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endothelin-1 and fibronectin. PKC also increases leucocyte adhesion through upregulation 
of intracellular adhesion molecules leading to capillary leakage, occlusion and 
microthrombosis. PKC activation mediates inhibition of Na+K+ and Ca2+ ATP-ase activity 
contributing to reduction in membrane transporter activity and thus changes in nerve 
conduction, microcirculatory flow and capillary pressure (Casellini et al, 2007). 
Described pathways (Ido et al., 1996) act not individually but in connected interactions 
(Figure 2).  
 
Fig. 2. Interaction between oxidative stress, non-enzymatic glycation, protein kinase C and 
polyole pathway and their impact on target structures (ROS=reactive oxygen species, 
AGEP´s=advanced glycation end products, PKC=protein kinase C, PEDF=pigment 
epithelium derived factor, ang=angiopoietin, VEGF=vascular endothelial growth factor, 
TGF=tissue growth factor, NFκB=nuclear factor κB)  
2.5 Low C-peptide concentration 
Disregarding hyperglycemia, the risk factor for microangiopathy development is decrease of 
C-peptide concentration in type 1 diabetes mellitus (Ekberg et al., 2007). C-peptide is 
producted by beta-cells of pancreas together with insulin and is used as a marker of 
endogenous insulin secretion as it is just minimally metabolized by the liver. The claims that 
it is biologically inactive molecule are now overcome. The binding of C-peptide to till now 
non-identified cell receptor leads to activation of G-proteins, increase of intracellular 
calcium concentration, increase of protein kinase C activity, MAP-kinase activity, increase of 
many transcriptional factors (NFκB, c-Fos), nuclear receptor PPARǑ or antiapoptotic protein 
Bc12. On the cellular level, C-peptide improves nerve function and erythrocyte 
deformability by increase of Na+K+ATP-ase activity, improves the endothelial function and 
protects from microangiopathy by nitric oxide sythetase induction and has antithrombic 
effect by inhibition of adhesive molecules expression (P-selectine, ICAM1). It can inhibit the 
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apoptosis by increasing the Bc12 concentration and can diminish the glomerular filtration by 
not completely understood mechanisms.  
2.6 Angiotensin-converting enzyme 
Angiotensin-converting enzyme (ACE) is circulating enzyme, exopeptidase, which 
participates in the renin-angiotensin-aldosterone system (RAAS) regulating the extracellular 
fluids volume and arterial vasoconstriction. ACE is secernated by endothelial cells of lungs 
and kidneys and catalyses the conversion of decapeptide angiotensin I into octapeptide 
angiotensin II (AngII) which acts like vasoconstrictor. ACE degrades vasodilator bradykinin 
and also other vasoactive peptides. Beside this, RAAS has a function in immune system – it 
regulates the extravasation and chemotactic migration of leucocytes, increases the 
expression of adhesive molecules, chemokines and chemokine receptors. T lymphocytes, 
macrophages and dendritic cells contribute to increase of renin and Ang II releasing through 
production of TNF and IL-1. According to the recent information, RAAS and Ang II have 
influence on origin of autoimmune diseases (Tippisetty et al., 2011). Ang II acts also like 
growth factor regulating the cell growth and tissue expansion what can lead to cell 
hyperthrophy and fibrotic changes of tissues.   
2.7 Risk factors 
An important role of diabetes compensation in development of chronic diabetic complications 
was proved by multicentric randomized study Diabetes Control and Complication Trial 
(DCCT) between 1983 and 1993 (DCCT Research Group, 1993). 1441 patients with DM type 
1 (diabetes duration 1 – 15 years) were enrolled to the study, divided into two groups 
according to the treatment by either conventional or intensified insulin regimen. Children 
younger than 13 years did not participate but 195 adolescents were enrolled. The prevalence 
of micro- and also macrovascular complications was significantly less frequent in the group 
treated intensively compared to the conventionally treated group. The most of the patients 
consequently continued in the next study Epidemiology of Diabetes Interventions and 
Complications (EDIC) where all of the subjects underwent intensified insulin treatment. 
After 4 years of EDIC study, the prevalence of chronic complications was still higher in the 
group initially treated by conventional regimen despite actual good compensation. In the 
subgroup of adolescents, the intensified therapy led to decrease of the risk of retinopathy by 
53%, neuropathy by 60% and microalbuminuria by 60%. In the next following of subjects in 
EDIC study, these differences were enhanced – patients treated from the beginning by 
intensified regimen had lower prevalence of retinopathy by 74% and of microalbuminury by 
48% compared to the patients treated conventionally in the first phase. This study showed 
“the effect of metabolic memory” where each period of worsened compensation can 
negativelly influence the prognosis of the diabetic patient. Some studies with lower number 
of patients did not confirm the association between diabetes compensation and chronic 
complications (M. Javorka et al., 2005).  
Diabetes duration is also suggested as an important risk factor for development of chronic 
complications. The significant correlation between diabetes duration and autonomic 
neuropathy (based on at least one pathologic result in two cardiovascular tests – heart rate 
variability, systolic blood pressure decrease in orthostasis) was confirmed in the biggest 
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study focusing on chronic diabetic complications EURODIAB IDDM Complication Study 
(EURODIAB IDDM Complication study group, 1994) where 3250 patients with DM type 1 at 
the age 15 – 60 years took part. Similar correlation was not confirmed in some other studies 
(Scaramuzza et al., 1998) probably caused by different methods and lower amount of 
subjects. 
Other risk factors were identified – increase in diastolic blood pressure ≥ 90 mmHg, 
increased triacylglycerides > 1,7 mmol/l, decrease of serum HDL cholesterol < 1,0 
mmol/l, microalbuminuria > 20 µg/min, higher body mass index, presence of 
retinopathy, smoking and the period of puberty (Donaghue et al., 2009). The diabetes 
compensation in prepubertal period has lower impact on complication development 
compared to the period after gonadarche (Maguire et al., 2005). Many adolescents with 
DM type 1 have frequently worsened compensation due to endocrine changes in puberty 
leading to increase of insulin resistance (insulin like growth factor IGF-1, sexual 
hormones) (Court et al., 2008) but also due to excessive food intake, lack of physical 
activity, neglect of insulin treatment and hazardous behavior (alcohol, smoking, drugs, 
contraceptives).     
Despite long lasting hyperglycemia, another important risk factor is genetic predisposition 
of the subject due to gene polymorphisms of enzymes involved in the pathogenesis of 
chronic complications origin and development (Donaghue et al., 2005). Probably other 
factors exist – immunologic, epigenetic, etc., which are not clear at present. This fact 
would clarify the clinical experience that some patients despite long diabetes duration 
and poor compensation do not have any signs of complications and on the other hand, 
some patients with adequate compensation and short diabetes duration suffer from some 
forms of complications.  
3. Diagnostics 
Diagnostic range of diabetic microangiopathic complications extends as it responds to 
ascending demands. Classic investigations (neurological examination, eye background 
investigation, microalbuminuria) could verify clinical manifesting forms of chronic 
complications. Nowadays, huge impact is put on the early diagnostics of clinically silent 
forms that has led to development of many new possibilities. New approach in diagnostics 
is investigation of gene polymorphisms of enzymes involved in the pathogenesis of 
microangiopathy that enables the individual approach to the patient and perhaps the 
“customized” therapy in the future.   
3.1 Patient´s history and physical examination 
Subclinical form of diabetic neuropathy is characterized as the absence of clinical 
manifestations of neuropathy, but specific tests can reveal the presence of some 
abnormalities. Clinical form can affect sensory-motor or autonomic nerve fibers. In 
sensory-motor form, the patient complains of sensory disturbance - paresthesia, 
dysesthesia, impaired vibration and / or thermal sensitivity, eventually of pain 
(neuropathic pain), and motor disturbances - decrease in muscle strength. Decreased 
tendon reflexes can be determined. These disorders can be expressed symmetrically or 
asymmetrically (Shy, 2007).  
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In autonomic form symptoms of disorder of various organ systems can be expressed: 
- cardiovascular system: rest tachycardia, orthostatic hypotension, increased 
arrhythmogenesis of myocardium, cardiomyopathy, circulation instability, decreased 
tolerance of physical activity and heat, edema of lower limbs 
- gastrointestinal system (Kycina et al., 2011): dysphagia, odynophagia, gastroparesis – 
nausea, diarrhea, constipation, fecal incontinence 
- urogenital system: atonia of vesica urinaria, urine retention, common urinary tract 
infection, erectile dysfunction, painless while pressing testes 
- respiratory system: decreased lung functions, prone to infections (Ďurdík et al., 2010), 
decreased cough reflex sensitivity 
- sudomotoric system: feet anhidrosis, increased sweating of upper part of the body, 
sweating after food and at the night  
- endocrine system: asymptomatic hypoglycemia, hormonal contraregulation disorder 
- other: pupillary reflex disorder.  
We note the patient's general condition, status and trophic skin and skin appendages - 
temperature, color, sweating, hair, skin appearance (the presence of dry, peeling skin), nail 
condition, pressure sores, infections. It is also necessary to assess trophic, tone and strength 
of selected muscle groups, loss of muscle mass, the state of the vascular system (pulsation of 
peripheral arteries) and condition of ligament structures of feet (shaped arch of the foot). 
Angiologic investigation – duplex Doppler ultrasound, transcutaneous measurement of 
oxygen saturation and blood pressure in lower limbs – is useful to detect the peripheral 
circulatory disorders.   
Orientational neurologic instrumentary investigation involves (Consensus statement, 1988): 
- tactile sensitivity investigated by 10 g Semmes-Weinsteins monofilaments which is 
attached to the top of the toe, 1st metatarsophalangeal joint, 5th metatarsophalangeal 
joint and the heel, bilaterally. Sensitivity is violated if a patient does not feel three or 
more touches of eight. 
- vibration sensitivity investigated by graduated tuner (128 Hz). The tuner is attached to 
the thumb nail bed on the both legs. The tuner is graduated to 8 degrees, for damaged 
vibration sensitivity is considered the value of 3 or less at the age less than 50 years (the 
value 5 or less at the age over 50 years).  
- pain sensitivity investigated by non-spiky sharp device on the tibia and feet 
- thermal sensitivity investigated by glasses fulled by cold and hot water 
- tendon reflexes (Achillary tendon, pattelary reflex) investigated by neurological hammer 
According to the American Diabetes Association (ADA), the screening of diabetic 
neuropathy in adults is recommended to be done once a year by careful physical 
investigation involving examination of tactile, thermal, pain and vibration sensitivity and 
the examination of ankle reflexes. The combination of at least two tests reflects more than 
87% sensitivity for neuropathy detection (Boulton et al., 2005).   
Blood pressure. Measuring the blood pressure belongs to the basic investigations which can 
also reflect the diabetic nephropathy or cardiovascular disorders. It should be measured in 
calm, at least twice. Values more than 140/90 or more than the 90th percentile for certain age 
in children are regarded as hypertension and adequate therapy is set.   
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Eye examination by ophtalmologist including vision examination and eye background 
examination (color fundus photography or ophtalmoscopy) can detect manifesting forms of 
diabetic retinopathy. Slit lamp examination can investigate the spatial relations between 
retina and vitreous.  
The recommendation of complication screening is presented in table 4. 
 
 
Recommendation of 
screening frequency 
Methods Therapy 
Retinopathy 
Once a year in children at 
the age > 11 years with DM 
duration > 2 years or at the 
age 9 years in children with 
DM duration ≥ 5 years 
Ophtalmoscopy in 
mydriasis or 
photography of 
fundus 
Improvement of DM 
compensation laser 
therapy 
Nephropathy 
Once a year in children at 
the age > 11 years with DM 
duration > 2 years or at the 
age 9 years in children with 
DM duration ≥ 5 years 
Albumin 
concentration in the 
first morning urine 
portion or albumin / 
creatinin ratio 
Improvement of DM 
compensation 
therapy by ACE 
inhibitors, decrease 
of BP 
Neuropathy Consensus was not achieved
History, physical 
examination 
Improvement of DM 
compensation 
Macrovascular 
complications 
At the age 12 years 
Serum lipids every 5 
years, blood pressure 
once a year 
Improvement of DM 
compensation, 
decrease of BP 
Table 4. Recommendation for microangiopathy complications screening 
3.2 Laboratory examinations 
Advanced glycation end products (AGEP´s) are valuable markers for assessment of long-
lasting hyperglycemia. In common practice glycosylated hemoglobin is used. Its 
concentration closely correlates with glycemia within last three months and it is influenced 
by many factors like recurrent hypoglycemia and processes influencing the life of 
erythrocytes (hemoglobinopathy, hyperbilirubinemia, uremia, hypertriacylglycerolemia and 
other).   
Other AGEP´s - N-carboxymethyl lysine, N-carboxyalkyl lysine, pentosidine, 
methylglyoxal, imidasol - are used for evaluation of microangiopathy (Peppa et al., 2003). 
The parameter reflecting the glycemia during shorter period than glycosylated hemoglobin 
(because of its biological halftime) is modificated albumin – carbonyled albumin, 
carboxymethyl lysine albumin or glycosylated albumin. It is a marker of oxidative stress 
however further studies are necessary to confirm its importance as a predictor of chronic 
complications. 
Other possibility for evaluation of diabetic complications are plasma markers reflecting the 
endothel dysfunction as they are released into the blood stream in relation to the endothelial 
damage (Adeghate et al., 2006), i.e. von Willebrandt factor, thrombomodulin, P-selectine, E-
selectine, ICAM-1 (intracellular adhesive molecule), VCAM-1 (vascular cell adhesive 
molecule).  
www.intechopen.com
 
Diabetic Microangiopathy – Etiopathogenesis, New Possibilities in Diagnostics and Management 
 
47 
Diagnostics tests for diabetic nephropathy include urine sediment, protein urine test, 
microalbuminuria, urine and blood creatinine, blood urea and nitrogen. Microalbuminuria 
is usually set from 12-hour night urine sample while good glycemia compensation, normal 
blood pressure and without excessive physical activity. The result is considered as possitive 
when at least two from three urine samples investigated at the period 3 – 6 months with the 
one month distance interval are possitive. Investigation of metalloproteinase-9 in blood can 
detect earlier cases of kidney damage. Possible indicator of tubulopathy is N-acetyl-beta-D-
glucoseaminidase (NAG). Its positivity in urine precedes the positivity of microalbuminuria 
in diabetic nephropathy. In the early stage, filtered albumin does not pass into the urine due 
to increased reabsorbtion in the proximal tubule and only NAG is present. Next, the 
reabsorbtion capacity of tubules is exceeded and microalbuminuria together with NAG is 
positive, in the advanced stages of nephropathy the positivity of NAG is caused by 
glomerular basement membrane damage as well as by tubular cells destruction. NAG is set 
as a ratio to creatinine in the urine (upper border is 0,25 U/mmol of creatinine).  
3.3 Examination of autonomic nervous system 
Cardiovascular system can be investigated by heart rate variability (HRV) by spectral and 
frequence analysis using the Ewing´s battery of cardiovascular tests (deep breathing test, 
orthostatic test, Valsalve maneuver) (K. Javorka et al., 2008; Havlíčeková & Jurko, 2005). The 
frequency of heart rate is not absolutelly regular but it oscillates about the average value. 
The result is heart rate variability which is influenced by autonomic nervous system – 
parasympathetic and sympathetic system together with endocrine system and other 
mechanisms.  
In physiological condition HRV is significant as a consequence of cooperation of 
sympathetic and parasympathetic nerve fibers. In subclinical form of microangiopathy this 
balance is impaired and HRV is decreased. The first damaged non-myelisated nerve fibers 
in diabetic neuropathy is nervus vagus so rest tachycardia is a consequence of functional 
dominance of sympathicus (Maser & Lenhard, 2005). HRV is sensitive marker of heart rate 
regulation and activity of autonomic nervous system in adults, children and newborns 
(Havlíčeková et al., 2009). Heart rate variability is technically provided by computer system 
(VariaPulse TF4, Dimea Group, Olomouc, Czec republic) with telemetricaly scanning of R-R 
intervals by special software. The investigation is done in darken room, before noon, with 
avoiding of alcohol and smoking. Patient has loaded the monitorring belt around the chest 
to monitor the heart frequency which is telemetrically transferred into the computer. The 
subject is instructed (to lie, to stand up, again to lie, to make four deep breaths within 20 
seconds) according to the actual test. The result is the protocol with parameters of high, low 
and very low frequency. The results are compared to refference values for certain age and 
sex (Tonhajzerova et al., 2002). To avoid false positive results is not available to investigate 
the patients with known disorders of cardiovascular and nervous system.     
Other valuable method for early determination of microvascular complications is cough 
reflex sensitivity (CRS) (Čiljaková et al., 2009). Cough reflex is one of the defense 
mechanisms of respiratory system. The decreased cough reflex sensitivity is due to impaired 
nervus vagus function (as a part of reflex circle) and is detectable also in the first stages of 
microangiopathic complications (Behera et al., 1995). CRS is provided by inhalation of 
tussigenous matter in gradually increasing concentrations and is defined as the lowest 
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concentration of tussigenous aerosol which provokes the cough. Two parameters are set: C2 
as the lowest concentration of tussigen able to provoke the two coughs and C5 as the lowest 
tussigen concentration which provokes five and more coughs. As the tussigen capsaicin 
aerosol (hot pepper extract) is used, active in micromolar and izoosmolar concentration at 
pH 7,4. Capsaicin is diluted ex tempore in gradually increasing concentrations (0,61 – 1250 
µmol/l). Aerosol is prepared by the nebuliser which is a part of Koko Pulmonary Function 
Testing. The subjects should breath through the mouth (with the clipped nose). The 
nebulisation is directed by the computer system and the aerosol penetrates into the 
respiratory system within 400 ms. The higher capsaicin concentration is needed for two or 
five coughs the more damaged is nervus vagus and the more developed is diabetic 
neuropathy. Each patient has done the spirometry before CRS. The investigation is 
contraindicated in patients who suffered from acute respiratory infection in last 4 weeks, in 
patients with allergy on capsaicin and relatively contraindicated in subjects with chronic 
respiratory diseases (bronchial asthma, cystic fibrosis). These conditions damage the defense 
mechanisms of respiratory system (cilliar epithel, mucocilliar transport), cause the higher 
sensitivity of respiratory tract to tussigen and so cause the higher cough reflex sensitivity. 
Mentioned conditions would cause the false negative results in the target to diagnose 
diabetic neuropathy. Four weeks are necessary to repair the respiratory defense functions 
after acute respiratory infection (Varechová et al., 2007).   
Electrodermal activity (EDA) is simple non-invasive electrophysiologic method allowing to 
detect the changes in the ability of the skin to conduct the electric signals (Papanas et al., 2007). 
This skin ability depends on eccrine sweat glands activity which is regulated by cholinergic 
sympathetic nerve fibers and endocrine system through adrenalin concentration in the 
circulation. If sweat glands produce enough salt sweat, EDA examination detects lower 
electrical resistance and better electrical conductance. Subjects with diabetic neuropathy can 
have damaged also sympathetic nerve fibers leading to lower secretion of sweat. The decrease 
amount of sweat results in lower electrical conductance or higher resistance of the skin. EDA 
examination represents the sensitive method which can show the disorder of sweat gland 
acitivity and so is one of the possible method for diagnosis of neuropathy.  
3.4 Examination of peripheral nervous system 
Electrophysiologic examinations represent sensitive, exact and well reproducible methods 
for the diagnosis of neuropathy. The principle of electromyographic examination (EMG) is 
detection of action potentials arisen in muscle and nerve fibers. Commonly used is needle 
EMG and conductory examination of nerve fibers (Shabo et al., 2007). The most frequently 
examined are n.fibularis (motoric nerve), n. suralis (sensitive nerve), n.plantaris medialis 
and n.tibialis on lower extremities and n.medianus, n.ulnaris and n.radialis on upper 
extremities. EMG shows the muscle response to electric signal mediated by nerve fibers 
after injection of needle electrodes. Various action potentials, their shape, duration, number 
of phases and amplitude are evaluated while muscle contraction. The principle of 
conductory studies is irritation of peripheral nerve or nerve stem by electric impulses where 
the quality of nerve conduction (latention of response, velocity and amplitude) is evaluated. 
The dysfunction of nervous system results in decrease or even block of nervous conduction 
and decrease in the amplitude. The main advantage of EMG is the possibility to diagnose 
the subclinical form of diabetic neuropathy (Karsidag et al., 2005).   
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Quantitative examination of sensitive function represents the subjective diagnostic test 
based on patient´s indication. Unlike the clinical investigation of sensitivity, quantitatively 
exactly defined stimules are applied. The vibration sensitivity is evaluated by 
biotensiometer and by exactly defined vibration stimulus (Kincaid et al., 2007). Device CASE 
(computer assisted sensory examination) enables to determine the threshold of vibration, 
pain and thermal sensitivity. Standard test algorhitms are used and the results are compared 
to the refference values considering the localisation and kind of stimulus, sex, age and 
anthropologic parameters of the patient. The conductory threshold for three types of 
sensitive fibers (A beta, A delta and C) and pain threshold by superficial electric stimulation 
with 5, 250 and 2000 Hz frequency can be detected by new device Neurometer. The 
computerized system of randomly generated stimuli enables to define the accuracy of 
patient´s response.  
3.5 Organ specific examinations 
Several methods help to diagnose the diabetic gastrointestinal autonomic neuropathy, like 
esophagogastroscopy or gastrointestinal passage. Special endoscopic device enables to 
combine manometry and EMG signal registration in each parts of gastrointestinal system. 
New method is electrogastrography measuring the gastric myoelectrical activity from 
electrodes placed on the surface of epigastrium. In diabetic gastropathy, the normal 
electrical rhythm (3 cycles per minute) is replaced with bradygastria, tachygastria, mixed or 
nonspecific dysrhythmia (Koch, 2001). Gastric motility can be examined by 13C octanoic acid 
breath test (Choi et al., 1997).   
Diagnostic of diabetic urogenital neuropathy is possible by urodynamic examination, 
cytoscopy or ultrasound of urinal residuum. For the diagnosis of sudomotoric neuropathy 
colour skin tests with changing colours depending on sweat amount are available. QSART 
test (quantitative sudomotor axon reflex test) and TST test (thermoregulatory sweat test) are 
not available in common practice.  
Respiratory complications (Brndiarová et al., 2011) of DM can be detected by lung 
function tests like spirometry, diffuse lung capacity for carbone monoxide or body 
plethysmography.  
Examination of pupillary reflex latention is possible by classic investigation and also by 
infrared reflex pupillography. New non-invasive examination for early microangiopathy 
detection is corneal confocal microscopy which quantifies the pathology of small nerve 
fibers in cornea (Hossain et al., 2005). Cornea is the most dense innervated part of human 
body, contains A delta and C nerve fibers. Corneal confocal microskopy enables to analyse 
the density of corneal nerves, their morphology or branching.   
Possible methods for diagnostics of diabetic retinopathy are fluorescein angiography 
showing retinal circulation, Amsler grid identifying what parts of visual field are damaged 
or eye ultrasonography used in the cases of vitreous hemorrhage or cataract. 
Fluorophotometry enables to measure posterior vitreous penetration ratio as the parameter 
reflecting the blood-retinal barrier permeability. New diagnostic tool for diabetic 
retinopathy and macular degeneration using LED technology is in development.  
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3.6 Gene polymorphisms detection 
The new approach in diabetic microangiopathy diagnosis is establishment of gene 
polymorphisms for single enzymes which enables the individual approach to the patient.   
Aldose reductase, rate-limiting enzyme of polyole patway, converts glucose into sorbitol in 
NADPH-depending reaction. Consequently, sorbitol is converted into fructose by enzyme 
sorbitol dehydrogenase using NAD+ as a cofactor. In hyperglycemia condition glucose 
conversion by this way is increased leading to many metabolic and vascular abnormalities. 
Gene AKR1B1 for aldose reductase can appear in several variations which are associated 
with development of diabetic neuropathy, retinopathy and nephropathy. According to 
Donaghue et al. (Donaghue et al., 2005) genotype Z-2/Z-2 represented the predisposition to 
earlier development of neuropathy. Contrary, Z+2 allele was regarded as protective in 
relation with neuropathy development (Z=138bp in (CA)n repetitive sequence). 
Establishment of aldose reductase gene polymophisms in diabetic population could be 
important as aldose reductase inhibitors (epalrestat, fidarestat) have successfully been used 
the some studies. This is the first step to the “individually tailored therapy” when aldose 
reductase inhibitors could be taken in patients carrying genotype predisposing to diabetic 
neuropathy.  
Uncoupling proteins (UCP1, 2, 3) are proteins in the inner mitochondrial membrane which 
are important in oxidative phosphorylation process, thermogenesis and also in protection 
against reactive oxygen and nitrogen species. UCP proteins reduce inner membrane 
potential through dispersion of protein gradient over mitochondrial membrane and so 
mitochondrial production of reactive oxygen species is decreased. G-866A polymorphisms 
in UCP 2 gene and C-55T polymorphism in UCP3 gene were associated with diminished 
risk of diabetic neuropathy development in diabetic patients (Rudolfsky et al., 2006).  
Decreased activity of membrane pump Na+K+ ATPase plays significant role in 
microvascular, mainly in neuropathy pathogenesis. It is coded by several genes. ATP1 A1 is 
predominantly expressed in peripheral nerves and erythrocytes. Patients with type 1 
diabetes who were the carriers of ATP1 A1 allele were more frequently affected by diabetic 
neuropathy (Vague et al., 1997). Identification of this risk factor can contribute to the 
prevention of neuropathy in the future.   
Antioxidant enzymes are crucial in prevention against oxidative stress. Glutathione-S-
transpherase (GST) represents huge family of GST isoenzymes which catalyze the 
conjugation of glutathione with electrophilic substrates resulting in less reactive and easily 
eliminated compounds. Substrates for this reaction are many carcinogens, drugs and also 
reactive oxygen species arisen in oxidative stress. The most intensively studied 
polymorphisms are genes of GST T1, GST M1 and P1. Null genotype of GST T1 and also 
null genotype of GST M1 significantly correlated with risk of coronal atherosclerosis 
(Manfredi et al., 2009). Deficit of GST as the result of null polymorphism of GST M1 and T1 
was significantly related to the decreased heart rate variability which is a consequence of 
oxidative stress influence on autonomic nerve system (Probst-Hensch et al., 2008). 
Association between GST T1 and M1 polymorphisms with DM is not completely clear and 
differ according to the authors, region and population. Some studies claimed higher risk of 
DM 2 in GST T1 null and T1 null / M1 null genotype (Hori et al., 2007), according to another 
study, in contrary, the presence of GST M1 allele was risk factor for development of DM 1 
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and M1 null allele was regarded as a protective (Bekris et al., 2005). Some authors did not 
find any significant relation between GST polymorphisms and diabetic neuropathy (Zotova 
et al., 2004). GST T1 null genotype was associated with chronic kidney disease in diabetic as 
well as non-diabetic subjects disregarding GST M1 genotype (Datta et al., 2010). Similarly, 
GST M1 null genotype seemed to have no influence on end stage renal disease while GST T1 
null genotype increased this risk in diabetic patients (Y. Yang et al., 2004). In young adults 
(average age 27) with DM1 was shown that GST M1 wild genotype represented a risk factor 
for diabetic retinopathy but not nephropathy. GST M1 null/T1 null combination did not 
increase the risk of microvascular complications (Hovnik et al., 2009).  
Superoxide dismutase (SOD) catalyzes the conversion of superoxide into oxygen and 
hydrogen peroxide, which is split by catalase into water and oxygen. According to (El 
Masry et al., 2005), frequency of Ala/Ala genotype of Mn-SOD2 was significantly lower in 
patients with diabetic neuropathy and the genotype Val/Val was significantly higher in 
patients without neuropathy.    
Hydrogene peroxide is harmful side product of many metabolic processes, so as the 
prevention from damage it has to be converted into less harmful substance. Catalase is 
enzyme localized in peroxisomes, functionally able to degrade the hydrogen peroxide into 
water and oxygen. In the study of C1167T marker of catalase gene has been shown, that C 
allele prevalence was more and T allele prevalence was less frequent in patients with 
diabetic neuropathy compared to the patients without neuropathy (Strokov et al., 2003). 
According to another study (Christiakov et al., 2006), 262 TT genotype of catalase gene was 
associated with higher activity of this enzyme in erythrocytes compared to the 262CC 
genotype. These results supposed protective effect of 262 TT allele against rapid neuropathy 
development.  
Paraoxonase is a group of enzymes associated with HDL – cholesterol which plays role in 
hydrolysis of organophosphates and has also antioxidant potential. Three genotype forms of 
paraoxonases (PON) have been described till now. PON1 is synthesized in the liver and 
transported together with HDL into plasma. Its function is to prevent oxidation of LDL 
cholesterol. Inflammatory changes and LDL cholesterol serum level influence plasma 
concentration of PON1. PON2 is ubiquitously expressed enzyme which protects cells 
against oxidative damage. PON3 has different substrate specificity as PON1. Its 
concentration is not influenced by inflammatory factors and oxidized lipids. As PONs act in 
prevention of oxidized LDL formation and so in prevention of atherogenous plaques they 
reduce the risk of atherosclerosis and ischemic heart disease. 192 Gln/Arg polymorphism of 
PON1 presented the risk of myocardial infarction in young patients till 45 years while in 311 
Ser/Cys PON2 polymorphism was not proved similar relation (Gluba et al., 2010). 
Association between DM and its complications with PON polymorphisms has not been 
found till now however decreased activity of this enzyme was described in patients with 
DM 1 as well as in patients with diabetic retinopathy compared to the healthy subjects 
(Ikeda et al., 1998).  
The first and rate-limiting enzyme in myoinositol pathway is myo-inositol oxygenase 
(MIOX). Increased level of MIOX directly depends on increased glycemia and can be the 
cause of myo-inositol depletion in patients with diabetic complications. English authors 
studied single nucleotide polymophisms (SNP) in patients with DM type 1. These patients 
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had decreased frequency of genotype combination CC (rs761745), GG (rs2232873) and GC 
(rs1055271) and less common haplotypes T/G/C and T/G/G compared to the healthy 
subjects (B. Yang, 2010).  
I (insertion) / D (deletion) polymorphisms of angiotensin-converting enzyme (ACE) is 
characterized by presence (I) or deletion (D) of repeating sequency (287 bp) in introne 16. 
According to the combinations of alleles subjects with I/I, I/D and D/D ACE genotypes 
exist. Homozygotes D/D have nearly twice higher concentration of ACE compared to I/I 
homozygotes. Regarding ACE influence on capillary diameter, organ vascularisation and 
also inflammatory and autoimmune processes, ACE polymorphisms can effect also 
development of DM and its complications. Turkish authors claimed significantly more 
frequent prevalence of D/D ACE polymorphism in patients with DM type 2 compared to 
healthy subjects (Arzu Ergen et al., 2004). D/D genotype of ACE has been suggested to be in 
association with diabetic nephropathy in DM2 patients (Naresh et al., 2009). According to 
another study frequency of I allele was significantly higher in diabetic patients with 
polyneuropahty compared to diabetic patients without neuropathy. D allele was regarded 
as protective against neuropathy (Ito et al., 2002).   
Determination of gene polymorphisms extends diagnostics of diabetic complications, 
enables individual approach to the therapy and gives the base for the “individually tailored 
therapy” in the future.  
4. Management  
Regarding the complex ethiopathogenesis, the management approach is also large. Till now, 
the only proved method how to slow the development of microangiopathic complications is 
maintain the optimal glycemia, even it is known that hyperglycemia is not the only one 
factor triggering the pathogenesis pathways. Arrangements contributing to euglycemia are 
also physical activity and adequate diet. As a supporting therapy, antioxidant alpha-lipoic 
acid is used although its effect was clearly proved just in intravenous application. L-
carnitine and vitamins B have neuroprotective effect, vitamin C and E dispose of just poor 
antioxidant acitivity. Common possibility, expecially in adult patients, is symptomatic 
therapy like tricyclic antidepressants or pregabalin in diabetic neuropathy, ACE inhibitors 
in diabetic nephropathy, laser therapy in retinopathy. Another therapeutic options are in 
experimental line mostly proved in animal models, till now.  
4.1 Euglycemia maintenance 
Despite of various experimental and clinical studies, the therapy of microangiopathy 
remains insufficient.  The only possible therapeutic approach which is concurrently clinicaly 
proved, is sufficient compensation of diabetes melltitus (Mokáň et al., 2009). The biggest 
study aimed at chronic diabetic complications, EURODIAB IDDM Complication Study, 
confirmed the significant correlation between glycosylation hemoglobin level and 
cardiovascular neuropathy. Even some authors denied this relation (M. Javorka et al., 2005), 
the optimal glycemia maintenance is strongly recommended as a prevention of diabetic 
complication origin. Children diabetic patients are treated by intensified insulin regimen. 
Patients with poor compensation are fully indicated to insulin pump therapy which best 
imitates the natural pancreatic secretion of insulin.  
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4.2 Dietary adjustment 
Adequate physical activity and dietary style also attitude to euglycemia maintenance. 
Diabetic patients should avoid food with high content of sugar, food with higher 
concentration of fats and meals prepared by high temperature (fried, grilled) as these have 
excessive ammount of AGEP´s. Contrary, fruit, vegetable and boiled or steamed meals 
content lower concentration of these products.  Prevention and treatment of diabetic 
nephropathy require also reducing salt intake at least less than 5-6 g per day. Advanced 
cases need restriction of phosphorus and potassium intake, as well. With advancing renal 
disease, protein compound should represent at the most of 20% of whole energy intake. 
Protein restriction of as much as 0.6 – 0.8 g/kg/day may retard the progression of 
nephropathy. 
4.3 Symptomatic therapy 
According to ADA recommendation (Boulton et al., 2005), painful form of diabetic 
neuropathy can be influenced by tricyclic antidepressives (e.g. amitryptilin 25 – 100 mg). 
However, the using of these drugs is limited in many patients because of anticholinergic and 
central side effects. From the group of anticonvulsives, gabapentin (1,8 g per day) and 
pregabalin are used (Rybka, 2007). Non-steroid antiphlogistics (ibuprofen, naproxen, 
indomethacin) are recommended only for short time due to their gastric side effects. The 
symptoms of diabetic autonomic neuropathy can be relieved by beta-blockers or ACE 
inhibitors. Other sympthomatic therapy is presented in table 5.  
 
Symptoms Therapy 
Pain 
Gabapentin, lamotrigin, pregabalin, temporary NSAID, 
magnetotherapy 
Rest tachycardia Cardioselective beta - blockers 
Ortostatic hypotension Sufficient ammount of fluids, bandage of lower extremities 
Excessive sweating Oxybutinin, glycolpyrolate 
Gastroparesis, constipation Prokinetics (metoclopramid, domperidon) 
Diarrhoea  Probiotics, diet 
Constipation  Lactulose, prokinetics 
Urine residuum Betanechol, doxazosin 
Table 5. Symptomatic therapy of diabetic neuropathy 
In the case of dyslipidemia, hypolipidemic drugs are used however we try to avoid them in 
the childhood. Every urinary tract infection should be treated and the prevention maintained.   
Inhibitors of angiotensin-converting enzyme (ACE inhibitors) are drugs primarily used for 
treatment of hypertension and congestive heart failure. ACE inhibitors block the conversion 
of angiotensin I to angiotensin II. Therefore, they lower arteriolar resistance, increase venous 
capacity and decrease blood pressure, they increase cardiac output, lower renovascular 
resistance and lead to natriuresis. As the angiotensin II contributes also to ventricular 
remodeling and heart hypertrophy, ACE inhibitors prevent this effect. They cause the 
central enhancement of parasympathehic activity (Adigun et al., 2001) by which cardiac 
arrhythmia and sudden death are prevented. Angiotensin II induces several fibrogenic 
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chemokines, namely transforming growth factor and monocyte chemoattractant protein-1 
(MCP-1) which induces monocyte immigration and differentiation to macrophages 
augmenting extracellular matrix production and tubulointerstitial fibrosis (Amann et al., 
2003). Thus ACE inhibitors can slow the progression of diabetic nephropahty. ACE 
inhibitors are superior to beta-blockers, diuretics, and calcium channel blockers in reducing 
urinary albumin excretion in normotensive and hypertensive type 1 and type 2 DM patients. 
Another possibility is represented by angiotension II receptor blockers which do not inhibit 
the breakdown of bradykinin and are thus just rarely associated with side effects like dry 
cough or angioedema. Although, hyperkaliemia remains as serious adverse effect so 
potassium monitoring is neccessary during the therapy.    
Proliferative stages of diabetic retinopathy and some severe nonproliferative forms require 
prompt surgical treatment. Focal laser treatment (photocoagulation) can stop or slow the 
leakage of blood and fluid in the eye by laser burns of abnormal blood vessels. Scatter laser 
treatment (panretinal photocoagulation) can shrink and scar the abnormal blood vessels of 
the retina away from macula. Cryocoagulation represents additional operation to 
photocoagulation if this could not stop the development of prolipherative retinopathy. The 
treatment of macula edema involves focal laser treatment and intravitreal application of 
steroids (25mg triamcinolon). Vitrectomy can be used to remove blood from the vitreous or 
to remove scar tissue tugging on the retina. Surgery often slows or stops the progression of 
diabetic retinopathy but retinal damage and vision loss is possible.  
4.4 Supporting therapy 
Drugs with content of alpha-lipoic acid are used in diabetic patients with diabetic 
neuropathy (Ziegler, 2004).  It is an antioxidant acting as a coenzyme of oxidative 
decarboxylation of alpha-ketoacids. It is easily transformed from oxidative form into 
reduced dihydroform what claims about its antioxidant potential. Metaanalysis of 1258 
patients showed the improvement of neurological symptoms of diabetic neuropathy after 
intravenous treatment by alpha-lipoic acid (600 mg i.v. per day) (Ziegler et al., 2006). Unlike 
the intravenous therapy, the improvement of symptoms after peroral cure is not so clear. In 
40 adolescents with DM, no significant decline of quantitative markers of oxidative stress, 
changes in glycosylated hemoglobin concentration nor in microalbuminuria was found after 
three months of peroral treatment by alpha-lipoic acid (Huang & Gitelman, 2008).    
L-carnitine is common available nutritional supplement with function to transport fatty 
acids from cytoplasm into mitochondria thus help to utilise them. Its other role is 
antioxidant – to prevent the lipooxidation of fatty acids. In 34 of 51 children patients with 
DM type 1 (average age 12 years) was found diabetic neuropathy by nerve conductory 
examination. After two-months of treatment by L-carnitin (2 g / m2 per day) the 
improvement of nerve conduction by 44% was claimed in subjects with early stage of 
diabetic neuropathy (Uzun et al., 2005).  
Vitamins B are also used as an additional therapy. Vitamin B6 (pyridoxamin) acts like 
carbonyl groups scavenger thereby diminishes the origin of AGEP´s. Benfothiamin is a 
derivate of thiamin (vitamin B1) soluble in fats with higher biological availability (Haupt et 
al., 2005). Thiamin and benfothiamin are cofactors of transketolase, an important enzyme of 
pentose-phosphate pathway, in which some products of glycolysis are degraded and so 
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activation of metabolic pathways (AGEP´s formation, proteinkinase C formation) with 
tissue damage is prevented. Medicaments with content of gama linoleic acid (omega 6 
unsaturated essential fatty acid), like evening primrose oil or borage oil, are appropriate as 
this acid is an important compound of membrane phospholipids and has anti-inflammatory, 
anti-thrombic and anti-atherogenous effect (Scott & King, 2004). Vitamin C and E as 
antioxidants act primarily non-enzymatic, can scavenge only part of oxidation stress end 
products, what explain their poor effect to prevent diabetic complications.  
Vitamin D has an important role not only in calcium-phosphate metabolism but also in 
immune system and in renin inhibition (Agarwal, 2009). Patients with diabetes mellitus and 
especially with more advanced stages of diabetic nephropathy usually have lower levels of 
vitamin D and so are recommended to have supplementation of this vitamin. Vitamin D 
supplementation may reduce proteinuria in patients with diabetic nephropathy (deZeeuw et 
al., 2010).  
Sulodexide is glycosaminoglycan with antithrombic activity containing two compounds – 
80% of low molecular weight heparin and 20% of dermatan sulphate. Daily dose of 60mg 
(600 U) injected intramusculary during three weeks resulted in significant descrease of 
albuminuria and this effect lasted 3 – 6 weeks after drug withdrawal (Skrha et al., 1997). In 
the multicenter study, 237 diabetic patients with micro- or macroalbuminuria were treated 
by sulodexide 50mg per day for 6 months. Significant reduction of albuminuria was found 
similarly in type 1 and type 2 diabetes and was slightly greater in macroalbuminuric than in 
microalbuminuric patients (Blouza et al., 2010).   
Calcium dobesilate is a venotonic drug with influence on membrane protocolagen, blood 
viscosity, aggregability of erythrocytes and trombocytes and with inhibitory function on 
PAF (Platelet Activating Factor). Some studies claimed that peroral treatment by calcium 
dobesilate (2 g daily for 2 years) improved the blood-retinal barrier permeability (Ribeiro et 
al., 2006), however randomised, double-blind, placebo-controlled, multicentre trial 
involving 635 patients with type 2 diabetes and mild-to-moderate non-proliferative 
retinopathy showed that treatment with calcium dobesilate 1500 mg daily within five years 
did not reduce the risk of development of clinically significant macular edema (Haritoglou 
et al., 2009).  
4.5 Experimental possibilities 
Ohter therapeutic possibilities are in the experimental line, till now. Many of medicaments 
effective in aminal models have not been applied in humans so their beneficial effect cannot 
be clearly proved. Huge negative of mentioned studies is lack of clinical verifying in 
children population. 
Aminoguanidin is hydrazin derivative with its ability to bind reactive carbonyl compounds 
and so to prevent the formation of AGEP´s (Thornalley, 2003). It is available on Americal 
trade (75 mg tablets) as a nutritional supplement against aging and diabetic complications 
origin. According to double blind randomized study (Bolton et al., 2004) with 690 patients 
with diabetes type 1, aminoguanidin at the dose 150 – 300mg during 2 – 4 years had 
protective effect to diabetic nephropathy. Contrary, some studies do not claim its 
therapeutic activity (Birrell et al., 2000). 
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Alagebrium chlorid (ALT-711) splits kovalent bindings between proteins and glucose thereby 
helps to AGEP´s elimination (Little et al., 2005). Administration of alagebrium at the dose 210 
mg per os daily in 62 patients with arterial hypertension led to the significantly increase in 
arterial flexibility compared to the group of patients treated by placebo (Kass et al., 2001). 
Peppa et al. (Peppa et al., 2006) gave alagebrium 1mg/kg daily to diabetic mice what had 
consequence in decrease the serum advanced glycation end products and microalbuminury. 
Also effect on diabetic nephropathy is assumed but further research is necessary to confirm it. 
Recent studies showed beneficial effect of C-peptide substitution (Ekberg & Johansson, 
2008). 46 adult subjects with diabetes mellitus type 1 and early stage of diabetic neuropathy 
enrolled the double-blind placebo-controlled study. Three months therapy by C-peptide 
(1,8mg per day) together with insulin substitution improved the functions of peripheral 
nervous system.      
Inhibitors of aldose-reductase interfere directly into patophysiological process of sorbitol 
and fructose formation by polyole pathway. Epalrestat, ranirestat or fidarestat significantly 
improved the peripheral neuropathy in diabetic patients (Bril & Buchanan, 2006; Drel et al., 
2008). According to the clinical study (Hotta et al., 2006) where 289 adult diabetics (type 
1and 2) were treated by epalrestat (50 mg 3-times daily per os) within 3 years, the symptoms 
of diabetic neuropathy were significantly diminished compared to the 305 patients treated 
by placebo. The medicament is not available on common trade.  
Ruboxistaurin, selective PKC- ǐ inhibitor, can improve circulatory parameters of retina, can 
decrease macular edema, reduces microalbuminury and improves the symptoms of simpler 
form of diabetic neuropathy (Aiello et al., 2006). 20 adult patients with DM type 1 and 2 
treated by ruboxistaurin (32mg per day) within 6 months significantly improved in 
symptoms of neuropathy compared to the 20 patients treated by placebo (Cassellini et al., 
2007). In Japan, ruboxistaurin is farmaceutically produced for treatment of diabetic 
neuropathy, retinopathy and macular edema. In America and Europe it is used in the 
clinical studies, till now.  
Apfel at al. (Apfel et al., 2000) found in their study that subcutaneous administration of 
recombinant human neural growth factor (NGF) during 48 weeks did not improve the 
nervous system function in diabetic patients. Hernander-Pedro et al. (Hernandez-Pedro et 
al., 2008) in the experimental conditions confirmed positive result after treatment by all-
trans retinoic acid which stimulates the origin of NGF. An interesting study is also 
treatment by monosialic gangliosid GM1 which decreases the proinflammatory cytokines 
and increases the NGF in pancreatic cells by what extends their survival (Vieira et al., 2008). 
Erythropoetin, initially identified as a hemopoetic factor, is also expressed in the nervous 
system and probably has neuroprotective effect. Chattopadhyay et al. (Chattopadhyay et al., 
2005) deal with vectors gene transpher based on HSV (herpes simplex virus) which are 
originally replied in nervous fibers. They found that mice with induced diabetes had 
significantly enhanced the function of nervous system after HSV-mediated transpher of 
erythropoetin. 
The using of angiotensin growth factor is controversial. Intramuscular gene transpher of 
VEGF (vascular endothelial growth factor) to the rats with induced diabetes caused the 
higher velocity by the nervous system compared to the control group (Schratzberger et al., 
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2001). Contrary, VEGF induces angiogenesis and retina neovascularisation by what diabetic 
retinopathy is caused. Ranizumab and bevacizumab are monoclonal antibodies against 
VEGF. Several studies claimed their succesful using in patients with diabetic retinopathy 
and macular edema (Avery et al., 2006). The prospective trial evaluated the efficacy and 
safety of intravitreal bevacizumab in eyes with macular edema secondary to central retinal 
vein occlusion. Eyes were treated with 3 intravitreal injections of 1.25 mg at monthly 
intervals. After 18 months of follow-up, visual acuity was increased and central retinal 
thickness was decreased while no drug-related systemic or ocular side effects were observed 
(Zhang et al., 2011). The influence on diabetic neuropathy have not been described. 
Neuropatic pain can be relieved by magnetotherapy. Weintraub et al. (Weintraub et al., 
2003) proved significantly improvement of the pain after 3 – 4 months of wearing the 
magnetic lining in the shoes. Static magnetic field can penetrate to the 20 mm height and 
influence the nociceptors in the epidermis and dermis. 45 children at the age 5 – 17 years 
with diabetic neuropathy had significantly better velocity of nervous fibers after treatment 
by dynamic magnetic fields (Nikolaeva et al., 2008).       
5. Conclusion 
Diabetes mellitus is chronic disease with rising incidence where supraphysiologic 
concentration of hyperglycemia alters the biostructures in nuclear, cellular, tissue and organ 
level. Diabetes duration and compensation are not exclusive factors playing role in the 
etiopathogenesis of chronic diabetic complications. Recent studies have shown the impact of 
gene polymorphisms and have suggested the influence of other factors (epigenetic, 
immunologic). The fact that prevalence of microangiopathic complications increase with 
diabetes duration is undeniable but it is true in general not in individual view. Improvement 
of diabetes compensation is still the only known therapeutic possibility recommended to delay 
or prevent diabetic complications. However, some patients despite adequate compensation 
have some forms of complications and on the other hand, some subjects despite poor 
compensation and long diabetes duration do not suffer from any complications. Here, the 
importance of individual approach to each subject is shown as each one has the unique 
combination of gene polymorphisms predisposing or protecting him to diabetic complications 
origin. By this new knowledge, the advance from general to individual approach is possible. 
Huge hope with proceeding research is presented by new diagnostic and therapeutic options 
like “therapy to measure” according to the individual demand.    
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